Communiqués VivoSim Labs, Inc.

Actions

VIVS

US68620A3023

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 29/09/2026			Varia. 5j.	Varia. 1 janv.
0,2025 ^USD	-8,04%		-13,94%	-88,81%

16/09	VivoSim Labs, Inc. dévoile de nouvelles données cliniques de référence à l’EUROTOX 2026 sur les plateformes NAMkind 3D de foie et d’intestin humains	CI
01/09	VivoSim Labs prévoit de développer un modèle de foie de rat pour compléter sa plateforme de foie humain NAMkind	CI

Communiqués

23/09	VivoSim Labs Inc. (NASDAQ: VIVS) Uses Human 3D Biology to Streamline Drug Development	AQ
18/09	High-Impact Stocks DRK, VIVS, AEMD, GMG in the News	AQ
16/09	VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs	GL
03/09	VivoSim Labs (NASDAQ: VIVS) Opens New Pharma Opportunity	AQ
01/09	VivoSim Labs to Add Rat Liver Model to NAMkind Platform	GL
12/08	VivoSim: Fiscal Q1 Earnings Snapshot	AQ
06/08	VivoSim Provides Financial and Listing Compliance Update	GL
21/07	VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services	GL
16/07	VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor	GL
15/07	VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027	GL
14/07	VivoSim: Fiscal Q4 Earnings Snapshot	AQ
29/06	VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting	GL
28/04	VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing	GL
01/04	VivoSim Announces Pricing of up to a $4 Million Public Offering	GL
24/03	VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs	GL
03/03	VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales	GL
11/02	VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego	GL
29/01	VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China	GL
06/01	VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer	GL
14/08/25	VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer	GL
12/08/25	VivoSim: Fiscal Q1 Earnings Snapshot	AQ
13/05/25	VivoSim’s NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference	GL
07/05/25	VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference	GL
24/04/25	VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market	GL
23/04/25	VivoSim to Carry Forward Organovo 3D Bioprinting	AQ